QT Prolongation Due to Roxithromycin

Total Page:16

File Type:pdf, Size:1020Kb

QT Prolongation Due to Roxithromycin Postgrad Med J 2000;76:651–654 651 Postgrad Med J: first published as 10.1136/pmj.76.900.651 on 1 October 2000. Downloaded from ADVERSE DRUG REACTION QT prolongation due to roxithromycin A Woywodt, U Grommas, W Buth, W RaZenbeul Roxithromycin and other macrolide antimicro- placement of the apex beat, a prominent third bials are widely used for a broad variety of heart sound, coarse rales over both lung fields infections such as upper respiratory tract infec- and pitting oedema of both ankles. The patient tion and community acquired pneumonia. was taken to an intensive care unit. Acute myo- Prolongation of the QT interval, torsade de cardial infarction was ruled out and frusemide pointes polymorphic ventricular tachycardia, was begun intravenously. An electrocardio- and sudden death are well described but little gram (ECG) on admission showed sinus known adverse reactions common to all rhythm and incomplete left bundle branch macrolides. We report the case of a 72 year old block; QT intervals were normal (QT interval patient with congestive heart failure caused by 380 ms, corrected QT interval according to University of ischaemic heart disease who developed severe Bazett’s formula [QTc] 390 ms). Roxithromy- Hannover Medical prolongation of the QT interval after three days cin (Roussel UCLAF, Romainville, France) School, 30623 of treatment with roxithromycin. 150 mg twice a day was initiated for suspected Hannover, Germany: pneumonia. On the third hospital day, he was Department of Nephrology Case report transferred to a general medical ward. A Woywodt A 72 year old man presented with severe On admission there, the patient was gener- W Buth congestive heart failure. Three months earlier ally well with few pulmonary rales and mild he had been diagnosed with three vessel coron- pitting oedema of the ankles. An ECG showed Department of new ST depression in the left precordial leads Cardiology ary heart disease with moderately impaired left U Grommas ventricular function. Thallium scans had failed with a markedly negative T wave in V4 (fig 1). WRaZenbeul to demonstrate a distinct area of ischaemia, The most striking findings, however, were QT hence a decision had been made to refrain from and QTc intervals of 680 ms and 660 ms, Correspondence and reprint surgical treatment. Frusemide (furosemide), respectively (fig 1). Serum concentrations of requests to: Dr Alexander potassium, calcium, and both amiodarone and Woywodt, Department of digoxin, captopril, and aspirin had been begun Nephrology, University of whereas metoprolol had to be discontinued digoxin were normal. The patient denied chest Hannover Medical School, because of bradycardia. In view of the impaired pain; serum troponin T and creatine kinase Carl-Neuberg-Strasse 1, were repeatedly normal. Digoxin, roxithromy- 30623 Hannover, Germany left ventricular function, amiodarone was (email: [email protected]) started, instead of blocker, after recurrent cin, and amiodarone were discontinued and â http://pmj.bmj.com/ episodes of atrial fibrillation. On admission, the the patient taken to an intermediate care unit Submitted 16 September patient was severely dyspnoeic and appeared to permit continuous ECG monitoring. One 1999 week later he was discharged in good health Accepted 13 January 2000 acutely ill. Physical examination revealed dis- with no dyspnoea and peripheral oedema and On admission On day 3 with improved QT intervals (QT 460 ms, QTc 430 ms). V3 V3 Discussion The QT interval is often neglected during on September 29, 2021 by guest. Protected copyright. interpretation of the routine ECG. Even measurement of the QT interval is not trivial, particularly when a U wave is also present or V4 when there is gradual transition of the T wave V4 to the baseline. In general, the point at which the downslope of the T wave crosses the base- line can be used to determine the end of the QT interval,1 although an occasional ECG may still pose diYculties in this regard. Moreover, the QRS width should always be determined to V5 V5 exclude prolongation of the QT interval caused by widening of the QRS interval. The patient discussed here had a markedly 1 mV 1 mV prolonged QT interval after three days in hos- pital for congestive heart failure. In search of a cause for QT prolongation, inherited and 1 s 1 s acquired disorders must be considered. Irre- spective of the cause, however, markedly Heart rate 61/min Heart rate 55/min prolonged QT intervals confer a high risk of QT 380 ms QT 680 ms sudden death due to polymorphic ventricular QTc 390 ms QTc 660 ms tachycardia, particularly of the torsade de Figure 1 ECGs before and after roxithromycin treatment. pointes variant.2 Recent research has elucidated www.postgradmedj.com 652 Woywodt, Grommas, Buth, et al Postgrad Med J: first published as 10.1136/pmj.76.900.651 on 1 October 2000. Downloaded from Box 1: Drugs associated with Learning points 1–3 prolongation of the QT interval x Macrolides, as well as a broad variety of 1. Antimicrobial agents other drugs, may prolong the QT x Antimalarials (chloroquine, halofantrine, interval, cause torsade de pointes mefloquine, quinine) polymorphic ventricular tachycardia, and precipitate sudden death in susceptible x Macrolides (erythromycin, individuals roxithromycin, azithromycin, spiramycin) x If possible, macrolides should therefore be avoided in patients who already x Pentamidine receive drugs with a propensity to x Trimethoprim-sulfamethoxazole prolong the QT interval, such as 2. Drugs with predominant action on the amiodarone and histamine antagonists cardiovascular system x Class IA antiarrhythmic agents (disopyramide, quinidine, procainamide) QT prolongation. Rarely, central nervous sys- x Class IB antiarrhythmic agents tem disease or cardiac disorders such as myo- (lignocaine (lidocaine), mexiletine, cardial infarction alone account for prolonga- aprindine) tion of the QT interval. Our patient had x Class IC antiarrhythmic agents normal serum electrolytes and there were no (encainide) signs and symptoms nor laboratory evidence of ongoing cardiac ischaemia. x Class III antiarrhythmic drugs Prolongation of the QT interval has been (amiodarone, bretylium, sotalol) reported as a side eVect of numerous drugs (see x Atropine box 1).3 The patient reported here received a x Calcium antagonists (nifedipine) total of three drugs with a potential to aVect cardiac repolarisation. Before admission he Digoxin, digitoxin x had been on digoxin and amiodarone after sev- x Diuretics eral episodes of atrial fibrillation. Amiodarone x Vasodilators (prenylamine, lidoflazine, has a well documented range of side eVects, fenoxidil, bepridil) one of them being prolongation of the QT interval.3 Digoxin, too, can disturb cardiac 3. Drugs with predominant action on the 3 central nervous system repolarisation and prolong the QT interval. In hospital, roxithromycin (erythromycin 9-[O- x Amantadine [(2-methoxyethoxy)methyl] oxime]), a semi- x Antidepressants (amitriptyline, synthetic macrolide antibiotic,4 was given for doxepine), pimozide community acquired pneumonia. The propen- x Chloral hydrate sity of macrolides to prolong the QT interval is well documented5 and their ability to cause http://pmj.bmj.com/ Lithium x polymorphic tachycardia and cardiac arrest has x Phenothiazines (chlorpromazine, been described in anecdotal reports.6 Recently, thioridazine), haloperidol erythromycin was shown to block IKr, the rapid 4. Miscellaneous drugs delayed rectifier channel for potassium.7 Fac- x Corticosteroids tors that confer increased vulnerability for erythromycin induced QT prolongation are x Gastrointestinal procinetics (cisapride) still awaiting further elucidation, although x Histamine antagonists (astemizole, female sex has been proposed to be a risk on September 29, 2021 by guest. Protected copyright. terfenadine), particularly when used with factor.8 Interestingly, macrolides occasionally antifungals such as fluconazole, unmask an inherited long QT syndrome9; itraconazole, ketoconazole therefore, genetic vulnerability may also play a x Probucol part. Macrolides may also prolong the QT interval by interacting with the metabolism of Tacrolimus x other drugs that aVect cardiac repolarisation 5. Toxins such as histamine antagonists.10 x Arsenic We conclude that our patient had acquired x Organophosphates prolongation of the QT interval due to concomitant use of digoxin, amiodarone, and roxithromycin. Marked prolongation of the QT interval is associated with a high risk of genetics and molecular pathogenesis of con- polymorphic torsade de pointes ventricular genital long QT syndrome and at least six tachycardia, ventricular fibrillation and sudden forms of the disorder have been attributed to death, more so in patients with advanced myo- mutations in cardiac ion channels.1 In the cardial disease. Macrolides should therefore be patient reported here, an acquired cause of used with caution or, better still, avoided in QT prolongation was suspected since QT patients who already receive other drugs with a intervals had been normal on admission. Elec- propensity to prolong the QT interval. If mac- trolyte disturbances2 such as hypokalaemia or rolides cannot be avoided in these patients, for hypomagnesaemia, and drug eVects3 are example in chlamydial infection or legion- among the most frequent causes of acquired naire’s disease, we suggest they are used www.postgradmedj.com QT prolongation due to roxithromycin 653 Postgrad Med J: first published as 10.1136/pmj.76.900.651 on 1 October 2000. Downloaded from cautiously with close monitoring of the QT 6 Lee KL, Jim MH, Tang SC, et al. QT prolongation and tor- sade de pointes associated with clarithromycin. Am J Med interval. 1998;104:395–6. 7 Antzelevitch C, Sun ZQ, Zhang ZQ, et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT 1 Braunwald E, ed. Heart disease. A textbook of cardiovascular intervals and torsade de pointes. 1996; : medicine. 5th Ed. Philadelphia: W B Saunders, 1996: 114 J Am Coll Cardiol 28 and 684–6. 1836–48. 2 el-Sherif N, Turitto G. The long QT syndrome and torsade 8 Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions de pointes. Pacing Clin Electrophysiol 1999;22:91–110. of erythromycin. Influence of female sex.
Recommended publications
  • Ventricular Arrhythmias Associated with Lidoflazine: Side-Effects Observed in a Randomized Trial •Y
    European Heart Journal (1983) 4, 889-893 Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial •y- S. P. HANLEY AND J. R. HAMPTON Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, U.K. Downloaded from https://academic.oup.com/eurheartj/article/4/12/889/503490 by guest on 29 September 2021 KEY WORDS: Angina, exercise testing, lidoflazine, propranolol, ventricular tachycardia. Twenty-four patients received either propranolol, lidoflazine (Clinium), or propranolol/lidoflazine com- binations in a study designed to evaluate the effect of these drugs in angina pectoris. Five patients developed ventricular tachycardia when receiving either lidoflazine or lidoflazine and propranolol in combination; one of these patients died. In addition, one patient died suddenly while being treated with propranolol alone. Lidoflazine therapy was associated with a significant prolongation of the QT interval of the electro- cardiogram. Lidoflazine either alone or in combination with propranolol, appears to induce ventricular tachycardia. Introduction patients already being treated with a beta-blocking, Patients with ischaemic heart disease have an whose symptoms were not adequately controlled; increased risk of death and of developing arrhyth- the second protocol was designed for patients who mias: in any clinical trial of a potential therapeutic were receiving no other treatment other than sub- agent for angina, such events are likely to occur by lingual glyceryl trinitrate. None of thqse patients chance. During a study of lidoflazine we detected was in clinical heart failure. In each of these studies an unacceptable incidence of arrhythmias which exercise tolerance was assessed by treadmill testing led us to discontinue the investigation.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Studies on the Possible Mechanisms of Lidoflazine Arrhythmogenicity
    742 lACC Vol 4, No 4 October 1984 742- 7 Studies on the Possible Mechanisms of Lidoflazine Arrhythmogenicity GAD KEREN, MD, DAVID TEPPER, BA, BRENDA BUTLER, BA, WILLIAM MAGUIRE, MD, PHD, HOWARD WILLENS, MD, DENNIS MIURA, MD, PHD , JOHN C. SaMBERG, MD Bronx. New York Lidoftazine is a calcium channel blocking agent that is Dogsalso underwent programmed electrical stimulation effective and safe in the treatment of angina pectoris, while not receiving medications and then after incre­ but has been reported to be associated with sudden death mental doses of lidoftazine administered intravenously. when administered for the treatment of supraventricular Lidoflazinedid not cause spontaneous ventricular tachy­ arrhythmias. Studies were performed in dogs to deter­ cardia and did not lower the threshold of ventricular mine if lidoflazine caused a rise in serum digoxin con­ tachycardia induction. Combined administration of Ii­ centration that could cause arrhythmias or if it was di­ doflazine and digoxin did not facilitate arrhythmia in­ rectly arrhythmogenic. Dogsreceived chronic injections duction. These studies do not support a digoxin-lido­ of digoxin and then digoxin in combination with lido­ f1azine interaction or a direct arrhythmogenic action of ftazine. No increase in digoxin concentration was found. Iidoflazine. Several clinical studies (1-3) have shown the effectiveness Thus. we undertook studies in dogs to test if a digoxin­ and safety of lidoflazine in the control of angina pectoris. lidoflazine interaction exists and causes a rise in serum di­ However, in patients with atrial fibril1ation receiving digi­ goxin levels . Another series of studies used programmed talis therapy and being treated with Iidoflazine to convert electrical stimulation techniques to determine whether suc­ the supraventricular arrhythmia.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Drug Induced Long QT Syndromes: Lethal Reactions to ‘Benign Drugs’ - May/2005 Dr
    Drug Induced Long QT Syndromes: Lethal Reactions to ‘Benign Drugs’ - May/2005 Dr. R.G.Williams Long QT syndrome (LQTS) ¾ A disorder of myocardial repolarization characterized by a prolonged QT interval on ECG. ¾ ↑ risk of a characteristic life-threatening cardiac arrhythmia, known as torsade de pointes (TdP) VT. ¾ Drug induced usually with bradycardia ¾ Short-long cycles 2o VPBs ¾ Present with: z Palpitations z Syncope z Seizures z Sudden cardiac death (SCD) ¾ Congenital – 2 phenotypes z Romano – Ward: more common, purely cardiac • Autosomal dominant z Jervell + Lange-Nielsen: sensorineural deafness • Autosomal recessive ¾ At least 7 genes described LQTS 1 - 7 ¾ Affect Na and K channels ¾ Acquired LQTS may be a ‘forme fruste’ Acquired LQTS ¾ Commonest causes z Medications z Electrolyte disorders ¾ Others z Structural heart disease z Stroke + brain injury z HIV z Eating disorders May, 2005 1 Talk edited into handout by RAS Long QT of Hypocalcemia May, 2005 2 Talk edited into handout by RAS Drug Induced LQTS ¾ First recognized in 1920s – quinidine syncope ¾ Monitoring identified typical sequences in TdP in 1960s ¾ In the past decade, the single most common cause of the withdrawal or restriction of the use of drugs that have already been marketed has been the prolongation of the QT interval associated with polymorphic ventricular tachycardia, or torsade de pointes. ¾ Nine structurally unrelated drugs removed or severely restricted due to QT ↑ + TdP. Risk Factors for TdP ¾ Drug regimen: z Not usually an idiosyncratic event z ↑drug dose or
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Anaesthetic Guideline for the Management of Children with Long QT Syndrome SOP/Protocol Detail Owner: Dr
    Anaesthetic Guideline for the management of children with long QT Syndrome SOP/Protocol Detail Owner: Dr. Jutta Scheffczik Publication: December 2020 Review: December 2023 Aims To ensure the safety of paediatric patients with congenital or acquired long QT syndrome who need a general anaesthetic. It is anticipated that most patients will undergo anaesthesia in Leeds and this guideline is to support those patients who do need to have a general anaesthetic at their local hospital. Objectives 1.To provide guidance on the management of children with LQTS 2.To enable children to have minor surgery in their local hospital where appropriate 3.To improve equity and consistency in care across the Yorkshire and Humber CHD Network Background Long QT syndrome is a congenital or acquired channelopathy, impairing myocardial electrical conduction that results in impaired ventricular repolarization and can present clinically as recurrent syncope, pseudo-seizures, or sudden death. Patients with QT prolongation and LQTS are susceptible to the development of the characteristic polymorphic ventricular tachycardia, called Torsades de Pointes TdP. The prolongation of the QT interval caused by anaesthetic drugs and the sympathetic response to anaesthesia and surgery can trigger malignant arrhythmias in patients with long QT syndrome. Patients with a genetic predisposition to LQTS may be asymptomatic and may have a normal resting QTc interval, it is possible for an episode of torsade de pointes to occur for the first time during anaesthesia. Diagnosis The diagnosis of long QT syndrome should be made by a paediatrician, a paediatrician with an expertise in cardiology or a paediatric cardiologist. QT intervals need to be corrected for heart rate (QTc – routinely defined using the Bazzett formula) and are highly variable, but the abnormal corrected values are defined as a pre-puberty average of >470ms in males, >480ms in females.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • A Unitary Mechanism of Calcium Antagonist Drug Action '(Dihydropyridine/Nifedipine/Verapamil/Neuroleptic/Diltiazem) KENNETH M
    Proc. Nati Acad. Sci. USA Vol. 80, pp. 860-864, February 1983 Medical Sciences A unitary mechanism of calcium antagonist drug action '(dihydropyridine/nifedipine/verapamil/neuroleptic/diltiazem) KENNETH M. M. MURPHY, ROBERT J. GOULD, BRIAN L. LARGENT, AND SOLOMON H. SNYDER* Departments of Neuroscience, Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 72S North Wolfe Street, Baltimore, Maryland 21205 Contributed by Solomon H. Snyder, October 21, 1982 ABSTRACT [3H]Nitrendipine binding to drug receptor sites liquid scintillation counting were carried out as described (7). associated with calcium channels is allosterically regulated by a All experiments, performed in triplicate, were replicated at diverse group of calcium channel antagonists. Verapamil, D-600 least three times with similar results. (methoxyverapamit), tiapamil, lidoflazine, flunarizine, cinnari- Guinea pig ileum longitudinal muscles were prepared for zine, and prenylamine all reduce P3H]nitrendipine binding affin- recording as described by Rosenberger et aL (13) and incubated ity. By contrast, diltiazem, a benzothiazepine calcium channel an- in a modified Tyrode's buffer (14) at 370C with continuous aer- tagonist, enhances [3H]nitrendipine binding. All these drugeffects ation with 95% '02/5% CO2. Ileum longitudinal muscles were involve a single site allosterically linked to the [3H]nitrendipine incubated in this buffer for 30 min before Ca2"-dependent con- binding site. Inhibition of t3H]nitrendipine binding by prenyl- were as described Jim et aL amine, lidoflazine, or tiapamil is reversed by D-600and diltiazem, tractions recorded by (15). which alone respectively slightlyreduceorenhance H]mnitrendipine RESULTS binding. Diltiazem reverses the inhibition of [3H]nitrendipine binding by D-600.
    [Show full text]
  • Chemically Induced Or Drug Induced Tinnitus
    International Tinnitus Journal 2, 1-2 (1996) Chemically Induced or Drug Induced Tinnitus Claus-Frenz Claussen, M.D. Department of Neurootology - University E.N. T Clinic, Wiirzburg, Germany or approaching the truth about the clinical accompanying complaints include hearing disorders and F phenomenon of tinnitus from more and more tinnitus. Many patients complain of reduced hearing and possible aspects, it is important in the sense of understanding of speech. Frequent auditory complaints the old Aristotelean systematics of scientific thinking to include a high pitched noise and a sensation of ear choose various and alternating directions for regarding blockage. Diagnosis is elusive, but is eventually the phenomenon. Therefore, today I am also choosing a established. The neurotoxic complications are increased biochemical angle of view. in number and intensity when solvents are multiple in Our model of good and bad hearing, ear noise or tinnitus, number and are released in combination into the is primarily demonstrated in the dimension of physics environment. CTE is a chronic progressive disease. and modern data technology. Hearing is based on the Recently, a male patient, age 58, was seen in consultation transmission of physical sounds from the surrounding for severe tinnitus. A prior diagnosis of CTE had been world by resonance in space to the outer ear; the physical established 26 years ago, secondary to toxic inhalation amplifier of the middle ear; and finally by digital data of trichlorethylene vapors. Tinnitus was reported to have transmission from the cochlea via the hearing pathways been the initial symptom. The patient discovered the to the temporal lobe of the brain.
    [Show full text]
  • Inherited Heart Conditions Sudden Arrhythmic Death Syndrome
    Inherited heart conditions Sudden arrhythmic death syndrome In association with Contents Introduction 04 Understanding Your Heart The normal heart 07 Sudden cardiac death and Sudden Arrhythmic Death Syndrome (SADS) 09 What happens after an unexpected sudden death? 10 Conditions that cause SADS What causes SADS? 13 Long QT Syndrome (LQTS) 14 Brugada Syndrome 18 CPVT (catecholaminergic polymorphic ventricular tachycardia) 21 PCCD (progressive cardiac conduction defect) 22 IVF (idiopathic ventricular fibrillation) 23 Sodium channel disease 23 Structural heart disease 23 Mitral valve prolapse 24 SADS and your family Implications of a SADS death for close blood Relatives of the person who has died 27 Assessment at a clinic for inherited cardiac conditions 28 Everyday Life General lifestyle advice 37 Author: Drugs to avoid 38 Dr Elijah R Behr MD Looking Forward Senior Lecturer and Honorary Consultant Electrophysiologist, Cardiology and Cardiological Sciences, St George’s Hospital and University of London The future 49 Published by Cardiac Risk in the Young (CRY) and the British Heart Foundation. Technical terms 51 This booklet is not a substitute for the advice your doctor or cardiologist (heart For more information 57 specialist) may give you based on his or her knowledge of your condition, but it should help you to understand what they tell you. Index 58 Introduction Title of chapter Introduction Understanding your heart You may be reading this booklet because a relative of yours – perhaps a member of your own family – has died suddenly and unexpectedly. This is not only a tragedy for the person and all your family, but a great loss for society too.
    [Show full text]
  • A Computational Tool for Pathway-Based Rational Drug Repositioning Supplementary Information
    gene2drug: a Computational Tool for Pathway-based Rational Drug Repositioning Supplementary Information Francesco Napolitano1, Diego Carrella1, Barbara Mandriani1, Sandra Pisonero1, Diego Medina1, Nicola Brunetti-Pierri1,2, and Diego di Bernardo1,3 1Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (NA), 80078, Italy. 2Department of Translational Medicine, Federico II University, 80131 Naples, Italy 3Department of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, 80125 Naples, Italy. List of Figures S1 Relation between PPI network-based and pathway based approaches. Given a therapeutic gene and the set of pathways it is annotated to according to the different databases, the other genes in the same pathways are topologically closer to it in the PPI network as compared to randomly chosen genes. The average shortest path from the selected gene to other pathway members is reported on the y axis for each database. 3 S2 Size of intersection between existent evidence scores in the STITCH database (subset matched against the Cmap database) as a percentage of the total number of evidences. Numbers on the diagonal represent how many times a drug-target evidence exists divided by the total number of reported pairs. A \combined score" always exist if one of the other evidences exist, thus \combined score" covers 100% of the pairs. Conversely, an \experimental" score is only present for 14% of the pairs. The \Text mining" evidence strongly drives the \combined score" covering 61% of all the known protein-target interactions in STITCH. 4 S3 Relative luminescence units (RLU) in Hepa1-6 cells transfected with a plasmid ex- pressing the luciferase gene under the control of the GPT promoter and incubated with various concentrations of fulvestrant.
    [Show full text]